Review of “A pneumonia outbreak associated with a new coronavirus of probable bat origin”


One-Minute Summary

- Laboratory analysis of samples from seven patients with severe pneumonia (six are seafood market peddlers or deliverers) admitted to an intensive care unit in Wuhan.

Patient testing:

- All 7 patients tested positive for 2019-nCoV by real-time PCR of respiratory specimens when sampled 7-18 days after symptom onset.
- 5 patients were available for additional sampling (oral swab, anal swab, and blood for PCR) 18-29 days after symptom onset and all tested negative. All 5 patients were still symptomatic and in hospital.
- These 5 patients were also tested by serology and were IgG positive for viral antibody, 3 of whom were also IgM positive.
- Serial antibody detection was done in one patient at 7, 8, 9, and 18 days after symptom onset. There was a rise in IgM and IgG at 8 and 9 days, respectively.

Genomic and viral analyses:

- Whole genome sequences of 2019-nCoV were obtained from five patients and were >99.9% identical to each other, 79.5% identical to SARS-CoV, and 96.2% identical to bat coronavirus.
- Phylogenetic analysis showed that 2019-nCoV is closely related to a bat coronavirus.
- Virus was isolated from a single patient and was shown to use angiotensin-converting enzyme 2 (ACE2) as a receptor for cell entry. ACE2 is the receptor for SARS-CoV.
- In vitro neutralization assays showed that 2019-nCoV was not able to infect cells when incubated with 2019-nCoV IgG-positive patient sera or horse anti-SARS-CoV serum, suggesting there is a potential for cross-reactivity with SARS-CoV antibody.

Additional Information

- Antibody detection was done by ELISA using a bat SARSr-CoV Rp3 nucleocapsid protein antigen (shows 92% amino acid identity to 2019-nCoV and no cross reactivity to other human coronaviruses except bat SARSr-CoV).
- The real-time PCR assay used the 2019-nCoV spike (S) gene as a target.
- 2019-nCoV was found to bind to ACE2 receptors from human, bat, swine and civet, but not mouse.
- 2019-nCoV does not use the same cell receptor as MERS-CoV (DPP4) or seasonal coronavirus (APN).
Citation

Disclaimer
This document was developed by Public Health Ontario (PHO). PHO provides scientific and technical advice to Ontario’s government, public health organizations and health care providers. PHO’s work is guided by the current best available evidence at the time of publication.

The application and use of this document is the responsibility of the user. PHO assumes no liability resulting from any such application or use.

This document may be reproduced without permission for non-commercial purposes only and provided that appropriate credit is given to PHO. No changes and/or modifications may be made to this document without express written permission from PHO.

Public Health Ontario
Public Health Ontario is a Crown corporation dedicated to protecting and promoting the health of all Ontarians and reducing inequities in health. Public Health Ontario links public health practitioners, front-line health workers and researchers to the best scientific intelligence and knowledge from around the world. For more information about PHO, visit publichealthontario.ca.